Drug Trial Radar · NCT05063149
Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 18, 2022
Primary completion
Dec 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Franciscus GasthuisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Leiden University Medical Center; Maastricht University Medical Center; Erasmus Medical Center
- First posted
- Sep 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 10 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to reduce respiratory tract infections and wheezing in moderate-late preterms in the first years of life by bacterial lysate administration. Next to determine the correlation of biological markers with respiratory symptoms, immune protection and treatment effect.
Conditions
- Wheezing
- LRTI
- Premature
Interventions
Broncho-VaxomDrug
Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
PlaceboOther
Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of physician diagnosed lower RTI and wheezing episodes in the first year of lifeTime frame: In the first year of life.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Franciscus Gasthuis & Vlietland
Rotterdam, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.